Reference is made to the stock exchange announcements published by Observe
Medical ASA (the "Company") on 9 February 2022, regarding the commencement of
the subscription period in the rights issue (the "Rights Issue") and the receipt
of subscription rights in the Rights Issue by certain primary insiders and
certain close associates of primary insiders of the Company.

Ingerø Reiten Investment Company AS, a closely associated person of Terje
Bakken, chairman of the board of directors of Observe Medical ASA, has today, on
21 February 2022, exercised 5,166,861 subscription rights in the Rights Issue,
entitling Ingerø Reiten Investment Company AS to be allocated 5,166,861 offer
shares in the Rights Issue at a price per offer share of NOK 7.00, subject to
the Rights Issue being completed. In addition, the close associate has over
-subscribed for 547,425 offer shares (i.e. made a subscription for 547,425 offer
shares not covered by subscription rights in the Rights Issue). The close
associate is not guaranteed allocation of such over-subscribed shares, and the
number of offer shares allocated to the close associate for such over
-subscription, if any, may first be confirmed upon the Company's board of
directors' allocation of the offer shares in the Rights Issue pursuant to the
allocation principles set out in the prospectus dated 8 February 2022, expected
to be resolved on or about 24 February 2022.

Björn Larsson, CEO of Observe Medical ASA has today, on 21 February 2022,
exercised 22,297 subscription rights in the Rights Issue, entitling Björn
Larsson to be allocated 22,297 offer shares in the Rights Issue at a price per
offer share of NOK 7.00, subject to the Rights Issue being completed.

Per Arne Nygård, CFO of Observe Medical ASA has today, on 21 February 2022,
exercised 24,816 subscription rights in the Rights Issue, entitling Per Arne
Nygård to be allocated 24,816 offer shares in the Rights Issue at a price per
offer share of NOK 7.00, subject to the Rights Issue being completed. In
addition, the primary insider has over-subscribed for 175,184 offer shares (i.e.
made a subscription for 175,184 offer shares not covered by subscription rights
in the Rights Issue). The primary insider is not guaranteed allocation of such
over-subscribed shares, and the number of offer shares allocated to the primary
insider for such over-subscription, if any, may first be confirmed upon the
Company's board of directors' allocation of the offer shares in the Rights Issue
pursuant to the allocation principles set out in the prospectus dated 8 February
2022, expected to be resolved on or about 24 February 2022.

Please see the attached notifications of trade for further information regarding
the primary insiders'  and the close associate's subscription of offer shares
covered by subscription rights in the Rights Issue.

For further information about the Company, please contact:

Björn Larsson, CEO of Observe Medical,
Mobile: +46 76 620 17 25
E-mail: bjorn.larsson@observemedical.com

Per Arne Nygård, CFO of Observe Medical,
Mobile: +47 411 04 345
E-mail: perarne.nygard@observemedical.com

For information about the Rights Issue, please contact the Managers:

Carnegie AS, tel.: +47 22 00 93 40
DNB Markets, tel.: +47 23 26 81 01

About Observe Medical

Observe Medical develops and markets and sells innovative hospital products that
contribute to increased patient safety and a more efficient care system. The
company's ambition is to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in
combination with targeted M&A. The company's headquarter is in Oslo, Norway and
its operations is based out of Gothenburg, Sweden. Observe Medical has a direct
sales organization in the Nordics and a distributor network internationally.
Observe Medical's product Sippi® is the only automated digital urine meter with
possibility for wireless data transfer to the hospital patient data management
systems and hinders bacterial migration that can lead to urinary infections
(SippCoat®). Sippi® is CE marked and is currently being launched with focus on
selected markets and hospitals in Nordics and in Europe.